Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study

Hillmen, Peter; C. Rawstron, Andy; Brock, Kristian; Munoz-Vicente, S; Yates, Francesca; Bishop, Rebecca; H. Boucher, Rebecca; Macdonald, Donald; Fegan, Chris; M. McCaig, Alison; Schuh, Anna; R. Pettitt, Andrew; G. Gribben, John; Patten, Piers; Devereux, Stephen; Bloor, Adrian; P. Fox, Christopher; Forconi, Francesco; Munir, Talha

doi:10.1200/jco.19.00894

Public

Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study

Published in Journal of Clinical Oncology • Jul 11, 2019

Authors:

Peter Hillmen

Andy C. Rawstron

Kristian Brock

Abstract

PURPOSE: The treatment of chronic lymphocytic leukemia (CLL) has been revolutionized by targeted therapies that either inhibit proliferation (ibrutinib) or reactivate apoptosis (venetoclax). Both significantly improve survival in CLL and replace chemoimmunotherapy for many patients. However, individ...

Subject

Venetoclax

Ibrutinib

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!